Stimulation methodologies and apparatus for control of brain states

• US 7,551,956 B2
• Filed: 06/13/2005
• Issued: 06/23/2009
• Est. Priority Date: 07/20/2002
• Status: Active Grant

• Current Assignee: Flint Hills Scientific, LLC
• Original Assignee: Flint Hills Scientific, LLC
• Inventors: Osorio, Ivan, Bhavaraju, Naresh C.
• Primary Examiner(s): Marmor, II; Charles A
• Assistant Examiner(s): Natnithithadha; Navin
• Application Number:
  US11/151,386
• Publication Number:
  US 20050228461A1
• Time in Patent Office: 1,471 Days
• Field of Search: 600/544, 600/545, 128/905, 128/920, 128923-925, 607/2, 607/45, 607/58, 607/59, 607/63, 607/66
• US Class Current: 600/545
• CPC Class Codes: A61B 5/377 using evoked responses
• CPC Class Codes: A61B 5/4094 Diagnosing or monitoring seizure diseases, e.g. epilepsy
• CPC Class Codes: A61N 1/36064 Epilepsy
• CPC Class Codes: A61N 1/36067 Movement disorders, e.g. tremor or Parkinson disease stimulating motor muscle A61N1/36003

Abstract

A system for accessing the brain of a subject to record and/or stimulate brain stares thereof. The system includes control means, first accessing means having a plurality of contact surfaces configured to operatively connect the control means to the brain of the subject to provide three-dimensional stimulation thereof; second accessing means having a plurality of contact surfaces to operatively connect the control means to the brain of the subject to provide access thereto for the purposes of obtaining three-dimensional recordings of the brain electrical activity of the subject; and a waveform bank containing a plurality of stimulating waveforms. The control means is configured to operatively apply a first at least one of the stimulating waveforms of the waveform bank to the brain of the subject through the first accessing means and to assess acceptability within defined limits, as determined by preset criteria, of the subject'"'"'s response to the application of the at first least one of the stimulating waveforms.

Claims

1. A system for controlling at least one change in brain state of a subject comprising:

(a) receiving unit configured to receive a signal indicative of die subject'"'"'s brain activity;

(b) a waveform bank containing a plurality of, or waveform components of a plurality of, stimulation waveforms;

(c) output unit configured to deliver the at least one stimulation waveform to the brain of the subject; and

(d) signal processing unit configured to;

(1) analyze the signal indicative of the subject'"'"'s brain activity to determine at least one measure of brain excitability,

(2) determine when the measure of brain excitability reaches a prespecified level associated with a state change, and

(3) trigger the output unit to deliver a stimulation waveform; and

(e) control unit configured;

(1) to select from the waveform bank, or construct from waveform components in the waveform bank, a first stimulation waveform or train of waveforms,

(2) to assess therapeutic efficacy or safety of at least one stimulation with the selected waveform being delivered by the output unit to control the brain state of the subject or to control a level of brain excitability of the subject, and

(3) if the therapeutic efficacy or safety is determined to be ineffective or unsafe, to select or construct a second stimulation waveform from the waveform bank for use by the output unit; and

(f) wherein the output unit is configured to also determine orientation of the exogenous field in reference to the field generated by the epileptogenic zone, number and location of anodes and cathodes used by the output unit and their location in reference to the epileptogenic zone.

2. A system for controlling at least one change in brain state of a subject comprising:

(a) receiving unit configured to receive a signal indicative of the subject'"'"'s brain activity;

(b) a waveform bank containing a plurality of, or waveform components of a plurality of, stimulation waveform

(c) output unit configured to deliver the at least one stimulation waveform to the brain of the subject;

(d) signal processing unit configured to;

(1) analyze the signal indicative of the subject'"'"'s brain activity to determine at least one measure of brain excitability,

(2) determine when the measure of brain excitability reaches a prespecified level associated with a state change, and

(3) trigger the output unit to deliver a stimulation waveform; and

(e) control unit configured;

(1) to select from the waveform bank, or construct from waveform components in the waveform bank, a first stimulation waveform or train of waveforms,

(2) to assess therapeutic efficacy or safety of at least one stimulation with the selected waveform being delivered by the output unit to control the brain state of the subject or to control a level of brain excitability of the subject, and

(3) if the therapeutic efficacy or safety is determined to be ineffective or unsath, to select or construct a second stimulation waveform from the waveform bank for use by the output unit; and

(f) wherein the output unit is configured to determine the number and location of anodes and cathodes used by the output unit and the orientation of the electrical field generated thereby.

3. The system as described in claim 2, wherein the at least one change in brain state is a seizure.

4. The system as described in claim 2, wherein the receiving means receive signals from at least one 1-dimensional, 2-dimensional, or 3-dimensional electrode.

5. The system as described in claim 2, wherein the plurality of, or die waveform components of a plurality of, stimulation waveforms of the waveform bank are taken from the group consisting of waveforms generated using analog circuits. digital waveforms or components thereof, including numbers selected from tables or generated by evaluating mathematical functions.

6. The system as described in claim 2, wherein the waveform bank includes noise signals.

7. The system as described in claim 2, wherein the output means is configured to include at least one 1-dimensional, 2-dimensional, or 3-dimensional electrode.

8. The system as described in claim 2, wherein the output means is configured to deliver waveforms in a manner that creates turbulence or randomly varying field orientations.

9. The system as described in claim 2, wherein the at least one measure of brain excitability is determined passively through monitoring of at least one index selected from the group consisting of:

electrical activity, temperature, the concentration of chemical indices such as ions, excitatory or inhibitory neurotransmitters, calcium /calmodulin protein II kinase or glutamic acid decarboxylase,

10. The system as described in claim 2, wherein the at least one measure of brain excitability is determined actively by monitoring the brain'"'"'s response to ultrasound, near-infrared light, or paired-pulse stimulation.

11. The system as described in claim 2, wherein the at least one measure of brain excitability is determined using the output of a state change prediction or detection algorithm including, information about the intensity, duration, or spatial extent of at least one state change.

12. The system as described in claim 2, wherein the at least one measure of brain excitability is determined using the output of a seizure prediction or detection algorithm including, information about the intensity, duration, or spatial extent of at least one seizure , or seizure content.

13. The system as described in claim 2, wherein the determination of brain excitability reaching a prespecified level is obtained by determining a statistical significance of changes in brain excitability.

14. The system as described in claim 2, wherein therapeutic efficacy is assessed by comparing measures or indices of brain excitability before and after delivery of therapy.

15. The system as described in claim 2, wherein therapeutic safety is determined to be unsafe if it changes the physical or chemical measures of brain excitability, elicits an after discharge, increases the frequency, spatial extent or severity of seizures typical for the subject under treatment, or if stimulation elicits new seizure types or subclinical neurological dysfunction ascertainable using quantitative analysis.

16. The system as described in claim 2, wherein therapeutic safety is determined by tracking changes in physical indices such as electrical or brain temperature changes.

17. The system as described in claim 2, wherein therapeutic safety is determined by tracking changes in chemical indices such as changes in ion, excitatory or inhibitory neurotransmitter indices.

18. The system as described in claim 2, wherein changes in brain excitability are estimated from at least one measure selected from the group consisting of time including time from a previous state change, circadian rhythms, ultradian rhythms, total sleep time, luminance, body temperature, brain tissue, CSF or Satan concentrations of naturally occurring or administered compounds, and menstrual cycle.

19. The system as described in claim 2, wherein the first or second stimulation waveform or train of waveforms are selected or constructed using parameters that include the slopes of the rising and descending components of the pulse, polarity of the initial phase of the pulse, orientation of the electrical field in reference to the epileptogenic site, timing of delivery of pulses in reference to the time of onset of the brain state change and site of delivery of electrical pulses in reference to the epileptogenic zone or zones.

20. The system as described in claim 2, wherein one or more stimulation waveforms are assembled into an assemblage of sequences or trains of stimulation waveforms.

21. The system us described in claim 20, wherein the assemblage is performed according to a pre-specified pattern.

22. The system as described in claim 20, wherein the assemblage is performed randomly.

23. The system as described in claim 20, wherein the assemblage is configured so that inter-waveform-intervals are varied during the assembled sequence or train.

24. The system as described in claim 20, wherein an inter-waveform-interval variation of the assemblage is a function of changes in at least one characteristic of the received signal indicative of the subject'"'"'s brain activity.

25. The system as described in claim 20, wherein an inter-waveform-interval of the assemblage varies randomly.

26. The system as described in claim 20, wherein the assemblage is performed using waveforms that provide delayed charge-balancing.

27. The system as described in claim 20, wherein waveform of the assemblage may have a gradually reducing charge.

28. The system as described in claim 20, wherein the assemblage is configured to cause the resulting stimulation frequency to range between 0.01 Hz and 10,000 Hz.

29. The system as described in claim 20, wherein the sequences or trains of the assemblage are of unequal duration.

30. The system as described in claim 2, wherein delivery of stimulation stops automatically in response to changes in. physical or chemical indices or brain excitability.

31. The system as described in claim 2, wherein an assessment includes determination of whether excitability decreases to a level deemed indicative of change from an undesirable to a desirable or less undesirable brain state.

32. The system as described in claim 2, wherein an assessment includes determination of whether excitability increases to a level indicative of a change to a more undesirable brain state including to that corresponding to a seizure.